Loading
A phase 2 trial of Pyrotinib, Vinorelbine and Inetetamab in Breast cancer, run by Zhiyong Yu, with a status the registry has not verified recently.
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer is a phase 2 interventional study registered as NCT04963595 by Zhiyong Yu, with 100 participants planned, started 2021-08-01 and due to reach its primary completion in 2023-01-31. Interventions recorded: Pyrotinib, Vinorelbine, Inetetamab. Conditions recorded: Metastatic Breast Cancer.
Linked to the drug Inetetamab because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Inetetamab, Pyrotinib, Breast cancer (all types) and the tag pipeline.
Shares Inetetamab, Breast cancer (all types) and the tag pipeline.
Shares Pyrotinib and the tag pipeline.
Shares Pyrotinib and the tag pipeline.
Shares Vinorelbine, Breast cancer (all types) and the tag pipeline.
Shares Vinorelbine and the tag pipeline.
Shares Vinorelbine and the tag pipeline.
Shares Pyrotinib and the tag pipeline.